• Policy
• The aftermath of the COVID-19 Pandemic
• by Lee, Hye-Kyung Feb 3, 2023 05:54am

• Policy
• CDDC sets reimb standards for Inrebic Capsule
• by Lee, Tak-Sun Feb 3, 2023 05:54am

• Opinion
• [Reporter's view] Leader's responsibility
• by Feb 3, 2023 05:53am

• Company
• Enhertu quickly lands at general hospitals in Korea
• by Eo, Yun-Ho Feb 3, 2023 05:53am

• Company
• Generic for Forxiga competition in the 90 Billion market
• by Kim, Jin-Gu Feb 3, 2023 05:53am

• Policy
• Introduction of online electronic sign-off from February
• by Lee, Tak-Sun Feb 2, 2023 05:48am

• Policy
• A year after Abilify 1mg was released,
• by Lee, Tak-Sun Feb 2, 2023 05:48am

• Company
• Hanmi’s Rolontis makes USD 10 million in 3 mths
• by Kim, Jin-Gu Feb 2, 2023 05:48am

• InterView
• Takeda will lead industry with focus on Oncology
• by Eo, Yun-Ho Feb 2, 2023 05:47am

• Company
• Takeda's Exkivity launches as non-reimbursement
• by Eo, Yun-Ho Feb 1, 2023 05:52pm